Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1994-4-14
|
pubmed:abstractText |
The serum level of pseudouridine, a modified nucleoside deriving mainly from t-RNA catabolism, was evaluated in 66 acute leukaemia patients at diagnosis to investigate its diagnostic and prognostic value, and its potential as a parameter with which to classify subtypes of the disease. Serum pseudouridine, measured by high performance liquid chromatography, was increased in acute lymphoblastic leukaemia patients (90% according to the pseudouridine index, which is the serum pseudouridine/creatinine ratio), and in acute myeloblastic leukaemia patients (75% according to the pseudouridine index). The increase was higher in the L3 than in the L1 and L2 subtypes. In the acute lymphoblastic leukaemia group there was a highly significant inverse correlation between serum pseudouridine levels and the most common end-point parameters used to assess disease outcome in leukaemia (i.e., complete remission rate, disease-free survival, and overall survival). In addition, 83% of patients with serum pseudouridine values < 5.5 nmol/mL were alive and in complete remission 12 months after the initial diagnosis, while only 11% of patients with serum pseudouridine values > 5.5 nmol/mL were alive and none were disease-free after the same period. This study: 1. demonstrates that the diagnostic sensitivity of the pseudouridine index is high in adult acute lymphoblastic leukaemia and good in acute myeloblastic leukaemia; 2. suggests that the serum pseudouridine assay can contribute to the classification of adult acute lymphoblastic leukaemia; and 3. demonstrates unequivocally that both pseudouridine assay and the pseudouridine index are excellent independent prognostic markers for acute lymphoblastic leukaemia.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0009-9120
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
26
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
513-20
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8124867-Adolescent,
pubmed-meshheading:8124867-Adult,
pubmed-meshheading:8124867-Aged,
pubmed-meshheading:8124867-Aged, 80 and over,
pubmed-meshheading:8124867-Antineoplastic Agents,
pubmed-meshheading:8124867-Humans,
pubmed-meshheading:8124867-Leukemia, Myeloid, Acute,
pubmed-meshheading:8124867-Middle Aged,
pubmed-meshheading:8124867-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:8124867-Prognosis,
pubmed-meshheading:8124867-Pseudouridine,
pubmed-meshheading:8124867-Remission Induction,
pubmed-meshheading:8124867-Survival Rate,
pubmed-meshheading:8124867-Treatment Outcome,
pubmed-meshheading:8124867-Tumor Markers, Biological
|
pubmed:year |
1993
|
pubmed:articleTitle |
Serum pseudouridine in the diagnosis of acute leukaemias and as a novel prognostic indicator in acute lymphoblastic leukaemia.
|
pubmed:affiliation |
Dipartimento di Biochimica e Biotechnologie Mediche, CEINGE Centro Ingegneria Genetica, Naples, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|